Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization

Q3 Medicine
Marianna Pavlyha MD , Madeleine Hunter MD , Roman Nowygrod MD , Virenda Patel MD, MPH , Nicholas Morrissey MD , Danielle Bajakian MD , Yihao Li MS , Gissette Reyes-Soffer MD
{"title":"Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization","authors":"Marianna Pavlyha MD ,&nbsp;Madeleine Hunter MD ,&nbsp;Roman Nowygrod MD ,&nbsp;Virenda Patel MD, MPH ,&nbsp;Nicholas Morrissey MD ,&nbsp;Danielle Bajakian MD ,&nbsp;Yihao Li MS ,&nbsp;Gissette Reyes-Soffer MD","doi":"10.1016/j.jvssci.2024.100211","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>High lipoprotein (a) [Lp(a)] is associated with adverse limb events in patients undergoing lower extremity revascularization. Lp(a) levels are genetically pre-determined, with <em>LPA</em> gene encoding for two apolipoprotein (a) [apo(a)] isoforms. Isoform size variations are driven by the number of kringle IV type 2 (KIV-2) repeats. Lp(a) levels are inversely correlated with isoform size. In this study, we examined the role of Lp(a) levels, apo(a) size, and inflammatory markers with lower extremity revascularization outcomes.</p></div><div><h3>Methods</h3><p>Twenty-five subjects with chronic peripheral arterial disease (PAD) underwent open or endovascular lower extremity revascularization (mean age, 66.7 ± 9.7 years; Female = 12; Male = 13; Black = 8; Hispanic = 5; and White = 12). Pre- and postoperative medical history, self-reported symptoms, ankle-brachial indices (ABIs), and lower extremity duplex ultrasounds were obtained. Plasma Lp(a), apoB100, lipid panel, and pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNFα) were assayed preoperatively. Isoform size was estimated using gel electrophoresis and weighted isoform size (<em>wIS</em>) calculated based on % isoform expression. Firth logistic regression was used to examine the relationship between Lp(a) levels and <em>wIS</em> with procedural outcomes: symptoms (better/worse), early primary patency at 2 to 4 weeks, ABIs, and reintervention within 3 to 6 months. We controlled for age, sex, history of diabetes, smoking, statin, antiplatelet, and anticoagulation use.</p></div><div><h3>Results</h3><p>Median plasma Lp(a) level was 108 (interrquartile range, 44-301) nmol/L. The mean apoB100 level was 168.0 ± 65.8 mg/dL. These values were not statistically different among races. We found no association between Lp(a) levels and w<em>IS</em> with measured plasma pro-inflammatory markers. However, smaller apo(a) <em>wIS</em> was associated with occlusion of the treated lesion(s) in the postoperative period (odds ratio, 1.97; 95% confidence interval, 1.01-3.86; <em>P</em> &lt; .05). The relationship of smaller apo(a) <em>wIS</em> with reintervention was not as strong (odds ratio, 1.57; 95% confidence interval, 0.96-2.56; <em>P</em> = .07). We observed no association between <em>wIS</em> with patient reported symptoms or change in ABIs.</p></div><div><h3>Conclusions</h3><p>In this small study, subjects with smaller apo(a) isoform size undergoing peripheral arterial revascularization were more likely to experience occlusion in the postoperative period and/or require reintervention. Larger cohort studies identifying the mechanism and validating these preliminary data are needed to improve understanding of long-term peripheral vascular outcomes.</p></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"5 ","pages":"Article 100211"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666350324000221/pdfft?md5=51b8275b14785503ef1bd582d15e92f7&pid=1-s2.0-S2666350324000221-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JVS-vascular science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666350324000221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

High lipoprotein (a) [Lp(a)] is associated with adverse limb events in patients undergoing lower extremity revascularization. Lp(a) levels are genetically pre-determined, with LPA gene encoding for two apolipoprotein (a) [apo(a)] isoforms. Isoform size variations are driven by the number of kringle IV type 2 (KIV-2) repeats. Lp(a) levels are inversely correlated with isoform size. In this study, we examined the role of Lp(a) levels, apo(a) size, and inflammatory markers with lower extremity revascularization outcomes.

Methods

Twenty-five subjects with chronic peripheral arterial disease (PAD) underwent open or endovascular lower extremity revascularization (mean age, 66.7 ± 9.7 years; Female = 12; Male = 13; Black = 8; Hispanic = 5; and White = 12). Pre- and postoperative medical history, self-reported symptoms, ankle-brachial indices (ABIs), and lower extremity duplex ultrasounds were obtained. Plasma Lp(a), apoB100, lipid panel, and pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNFα) were assayed preoperatively. Isoform size was estimated using gel electrophoresis and weighted isoform size (wIS) calculated based on % isoform expression. Firth logistic regression was used to examine the relationship between Lp(a) levels and wIS with procedural outcomes: symptoms (better/worse), early primary patency at 2 to 4 weeks, ABIs, and reintervention within 3 to 6 months. We controlled for age, sex, history of diabetes, smoking, statin, antiplatelet, and anticoagulation use.

Results

Median plasma Lp(a) level was 108 (interrquartile range, 44-301) nmol/L. The mean apoB100 level was 168.0 ± 65.8 mg/dL. These values were not statistically different among races. We found no association between Lp(a) levels and wIS with measured plasma pro-inflammatory markers. However, smaller apo(a) wIS was associated with occlusion of the treated lesion(s) in the postoperative period (odds ratio, 1.97; 95% confidence interval, 1.01-3.86; P < .05). The relationship of smaller apo(a) wIS with reintervention was not as strong (odds ratio, 1.57; 95% confidence interval, 0.96-2.56; P = .07). We observed no association between wIS with patient reported symptoms or change in ABIs.

Conclusions

In this small study, subjects with smaller apo(a) isoform size undergoing peripheral arterial revascularization were more likely to experience occlusion in the postoperative period and/or require reintervention. Larger cohort studies identifying the mechanism and validating these preliminary data are needed to improve understanding of long-term peripheral vascular outcomes.

小载脂蛋白(a)同工酶可预测外周动脉血管再通术后的原发性通畅率
背景高脂蛋白(a)[Lp(a)]与接受下肢血管重建术的患者肢体不良事件有关。脂蛋白(a)水平是由基因预先决定的,LPA基因编码两种载脂蛋白(a)[apo(a)]异构体。异构体大小的变化受 kringle IV 2 型(KIV-2)重复序列数量的影响。脂蛋白(a)水平与异构体大小成反比。方法25名患有慢性外周动脉疾病(PAD)的受试者接受了开放或血管内下肢血运重建术(平均年龄66.7 ± 9.7岁;女性=12;男性=13;黑人=8;西班牙裔=5;白人=12)。研究人员采集了术前和术后病史、自述症状、踝肱指数(ABI)和下肢双相超声波检查。术前检测了血浆 Lp(a)、apoB100、血脂组合和促炎症指标(IL-6、IL-18、hs-CRP、TNFα)。使用凝胶电泳估算同工酶大小,并根据同工酶表达率计算加权同工酶大小(wIS)。我们使用 Firth logistic 回归来检验 Lp(a) 水平和 wIS 与以下手术结果之间的关系:症状(好转/恶化)、2 到 4 周的早期原发性通畅、ABI 和 3 到 6 个月内的再次干预。我们对年龄、性别、糖尿病史、吸烟、他汀类药物、抗血小板药物和抗凝药物的使用进行了控制。结果中位血浆脂蛋白(a)水平为 108(四分位间范围,44-301)毫摩尔/升。载脂蛋白 B100 的平均水平为 168.0 ± 65.8 mg/dL。这些数值在不同种族之间没有统计学差异。我们发现脂蛋白(a)水平和 wIS 与测量的血浆促炎标记物之间没有关联。然而,较小的载脂蛋白(a)wIS 与术后治疗病灶闭塞有关(几率比,1.97;95% 置信区间,1.01-3.86;P < .05)。较小的载脂蛋白(a)wIS 与再次干预的关系并不密切(几率比,1.57;95% 置信区间,0.96-2.56;P = .07)。结论在这项小型研究中,接受外周动脉血管再通手术的载脂蛋白(a)异构体较小的受试者更有可能在术后出现闭塞和/或需要再次干预。为了更好地了解外周血管的长期预后,需要进行更大规模的队列研究来确定机制并验证这些初步数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
0
审稿时长
28 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信